AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 81 min read$AVR

Anteris Technologies Global Corp. (AVR): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Financial Officer On September 4, 2026, Anteris Technologies Global Corp. (the “Company”) appointed B

Original reporting
SEC EDGAR 8-K
Published Sep 8, 2026, 11:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 11:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$AVR
Neutral
medium confidence
Mentioned
$AVR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AVRNeutralLow
01

Why it matters

The filing provides the first public disclosure of the CFO change, offering fresh data for investors.

02

Market read

Primary corporate action for a micro‑cap; limited immediate market impact but relevant for shareholders.

03

What to watch

Moen's prior experience at niche med‑tech firms could bring valuable expertise for upcoming product pipelines.

Relevance 6/10Novelty 6/10Timing: effective September 11, 2026

Background

SEC Form 8‑K filed by Anteris Technologies Global Corp details the CFO transition and related compensation.

Company-level read

Ticker impact

$AVRNeutralMedium confidence
Context

Anteris Technologies Global Corp filed an 8‑K announcing the appointment of Brent Moen as CFO effective September 11, 2026.

Expected impact

Potential modest upside if market views the hire positively; limited immediate price move.

Evidence & confidence

The filing is a primary disclosure of a senior executive change for a micro‑cap; impact depends on execution of growth plans.

Market effects

Sector

Minimal; CFO change in a medical‑technology micro‑cap does not shift sector dynamics.

Regional

None; company is US‑based with limited regional exposure.

Global

Low; the news is company‑specific and unlikely to affect broader markets.

Counterpoint

What could challenge this read

The appointment may signal internal challenges; investors could view the change as a red flag.

Key entities

  • company
    Anteris Technologies Global Corp.

    Micro‑cap medical‑technology firm filing the 8‑K.

  • person
    Brent Moen

    Newly appointed Chief Financial Officer.

Read at source← All news

Related articles

AUG 12
$AVRMed

Anteris Advances DurAVR Toward Commercialization; PARADIGM Trial Expands U.S. Recruitment

Anteris Technologies Global Corp. (AVR) reported Q2 2026 results and said it secured U.S. Medicare reimbursement eligibility for PARADIGM Trial procedures. The company began U.S. recruitment, with first patients treated in May 2026, and said the trial is recruiting in the U.S., Denmark and the Netherlands. Net operating cash outflow was $20.8M; R&D expense was $23.4M.

rttnews.com5 min
AUG 12
$AVRMed

Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway

Anteris Technologies (ASX:AVR, NASDAQ:AVR) said it advanced its pivotal PARADIGM Trial in the June quarter, enrolling and treating its first US patients after CMS Medicare reimbursement eligibility for qualifying procedures. Recruitment expanded to the US, Denmark and the Netherlands, with Canada and France receiving regulatory clearance. The trial targets about 1,000 patients. Net operating cash outflows were US$20.8m.

proactiveinvestors.com.au4 min
AUG 11
$AVRMedAI 8/10

Anteris Technologies Announces Results for the Second Quarter of 2026

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) reported Q2 2026 results for the quarter ended June 30, 2026. It said CMS granted Medicare reimbursement eligibility for the PARADIGM Trial, U.S. recruitment began with first patients treated in May 2026, and the trial expanded to multiple regions. Net operating cash outflows were $20.8M; R&D expenses were $23.4M.

leaderpost.com6 min
AUG 11
$AVRLow

Anteris Technologies Global Corp. (AVR): Results of Operations and Financial Condition

Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anteris Technologies Announces Results for the Second Quarter of 2026 MINNEAPOLIS, United States and BRISBANE, Australia August 12, 2026 (AEST) Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committe

SEC EDGAR 8-K4 min
JUN 4
$AVRMed

Anteris Technologies Global (NASDAQ:AVR) Shares Up 12.6% – Should You Buy?

Anteris Technologies Global (NASDAQ:AVR) shares rose 12.6% to $10.0750 on Thursday, after closing at $8.95; the stock traded between $9.71 and $10.0750. Volume was 176,960 shares, down 84% vs. average. Analysts cited mixed views: Barclays raised its target to $18 (overweight), while Wall Street Zen moved to hold; consensus target is $16. In its May 12 earnings, the company reported -$0.28 EPS vs -$0.27 expected on $0.49M revenue vs $0.77M.

tickerreport.com5 min